U.S. Vaccine Distribution Strategy is a Mess
Prognosis: Misconception
Bloomberg
4.1 • 838 Ratings
🗓️ 14 October 2020
⏱️ 17 minutes
🧾️ Download transcript
Summary
States are racing the clock to meet a Friday deadline from the Federal government to submit their plans to distribute a vaccine, once an effective one is ready. But Angelica Lavito reports that they’re putting together their strategies effectively blindfolded. State health officials have no clue which vaccine they will be distributing, nor when — or even if — a vaccine will be forthcoming.
See omnystudio.com/listener for privacy information.
Transcript
Click on a timestamp to play from that location
| 0:00.0 | What could you do if your data was working for you and not against you? With Bloomberg delivering |
| 0:07.3 | enterprise data directly to your systems, you get easy access to the details you want, optimized for |
| 0:14.1 | higher level analysis, and financial data experts committed to helping you maximize your every move. |
| 0:24.0 | Our data is made for more, so you can show the world what you're made of. Visit Bloomberg.com slash enterprise data to learn more. |
| 0:33.3 | Welcome to Prognosis. I'm Laura Carlson. It's day 217 since coronavirus was declared a global pandemic. |
| 0:43.7 | Today's main story? In the U.S., it's up to individual states to develop plans for distributing a vaccine. Once, one is available. But now, they face intense time pressure |
| 0:57.8 | to develop their strategies. And they're flying blind without necessary information about the |
| 1:04.5 | type and timing of the vaccines they'll be offering. But first, here's what happened in virus news today. |
| 1:13.6 | Food and Drug Administration Commissioner Stephen Hahn said that the recent pauses in several |
| 1:29.3 | clinical trials are a necessary step to making sure any COVID-19 vaccine or therapy will be safe. |
| 1:38.8 | In an interview with Bloomberg today, Han said that recent stops to clinical studies of vaccines and antibody treatments |
| 1:46.8 | by Johnson & Johnson, Eli Lilly, and AstraZeneca are normal. The system, he said, is designed this way |
| 1:55.1 | to identify safety issues and protect participants, but also to find the right treatments and vaccines in the end. |
| 2:04.1 | A surge in coronavirus infections in the U.S. is threatening the very survival of hospitals |
| 2:10.3 | just when the country needs the most. |
| 2:13.9 | Hundreds of facilities were already on shaky financial ground before the virus, |
| 2:19.3 | and the impact of caring for COVID patients has put hundreds more in jeopardy. |
| 2:25.5 | The pandemic sidelined profitable elective procedures and pushed up costs to keep patients and staff safe. |
| 2:38.0 | Meanwhile, hospitals are losing the privately insured patients they depend on as millions of Americans lose their jobs and their employer-sponsored |
| 2:45.0 | coverage. The American Hospital Association estimates the pandemic will cost U.S. hospitals more than $323 billion by the end of the year. |
| 2:57.6 | The industry group is asking Congress for an additional $100 billion, |
| 3:03.6 | and full forgiveness of loans made under Medicare's accelerated payment program, among other requests for relief. |
... |
Please login to see the full transcript.
Disclaimer: The podcast and artwork embedded on this page are from Bloomberg, and are the property of its owner and not affiliated with or endorsed by Tapesearch.
Generated transcripts are the property of Bloomberg and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.
Copyright © Tapesearch 2026.